Common blood pressure medicine blocks molecule that can trigger the disease
A drug commonly used to control high blood pressure may also help prevent the onset of Type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida (UF) in Gainesville.
The study was published online this week in the Journal of Clinical Investigation.
“This is the first personalized treatment for Type 1 diabetes prevention,” said Aaron Michels, MD, a researcher at the Barbara Davis Center for Childhood Diabetes and associate professor of medicine at CU Anschutz. “We made this discovery using a supercomputer, on the lab bench, in mice and in humans.”
The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children. It is on the World Health Organization’s list of essential drugs.
But like many drugs used for one condition, Michels and his colleagues found it useful for something totally unrelated.
Some 60 percent of people at risk of getting Type 1 diabetes possess the DQ8 molecule which significantly increases the chance of getting the disease. The researchers believed that if they could block specifically the DQ8 molecule they could also block the onset of the disease.
“All drugs have off-target effects. If you take too much acetaminophen you can hurt your liver,” Michels said. “We took every FDA-approved small molecule drug and analyzed HLA-DQ8 binding through a supercomputer. We searched a thousand orientations for each drug to identify those that would fit within the DQ8 molecule binding groove.”
After running thousands of drugs through the supercomputer, they found that methyldopa not only blocked DQ8, but it didn’t harm the immune function of other cells like many immunosuppressant drugs do.
The research spanned 10 years and its efficacy was shown in mice and in 20 Type 1 diabetes patients who took part in a clinical trial at the Barbara Davis Center at the University of Colorado School of Medicine.
“We can now predict with almost 100 percent accuracy who is likely to get Type 1 diabetes,” Michels said. “The goal with this drug is to delay or prevent the onset of the disease among those at risk.”
The drug is taken orally, three times a day.
Implications for treatment
Michels and UF Health researcher David Ostrov, PhD, hope this same approach of blocking specific molecules can be used in other diseases.
“This study has significant implications for treatment of diabetes and also other autoimmune diseases,” said Ostrov, associate professor of pathology, immunology and laboratory medicine in the UF College of Medicine and a member of the UF Health Cancer Center, Genetics Institute and Center for NeuroGenetics. “This study suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”
The next step will be a larger clinical trial sponsored by the National Institutes of Health in spring.
“With this drug, we can potentially prevent up to 60 percent of Type 1 diabetes in those at risk for the disease,” Michels said. “This is very significant development.”
The Latest on: Type 1 diabetes
via Google News
The Latest on: Type 1 diabetes
- Share-Worthy Diabetes Life Hacks on April 18, 2019 at 3:34 am
Everybody loves a good life hack. And they can sometimes be mission-critical when you're living with diabetes. Here are a few favorite (non-medical) type 1 diabetes tips and tricks from our team that ... […]
- Elevated Glycemic Gap Predicts Acute Respiratory Failure and In-hospital Mortality in Acute Heart Failure Patients with Diabetes on April 18, 2019 at 2:26 am
Diabetes is a common comorbidity in patients ... 95% confidence interval, 1.355–38.520) than those with glycemic gap levels ≤43 mg/dL. The B-type natriuretic peptide levels incorporated with glycemic ... […]
- Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes on April 18, 2019 at 2:21 am
The exclusion criteria were the following: type 1 diabetes or positivity for glutamic acid decarboxylase autoantibodies, secondary forms of diabetes, acute metabolic complications, liver disease, ... […]
- Experts Warn Diabetes Affects Daily Lives of Staff and Students on April 18, 2019 at 2:09 am
According to experts, there are three prominent subsets of diabetes mellitus, and they are Type 1, Type 2, and gestational diabetes. The WebMD has reported that with Type 1 diabetes, the immune ... […]
- Run The Risk: When An Athlete With Type 1 Diabetes Uses Himself As A Thesis on April 17, 2019 at 5:32 pm
Ian MacNairn faced a long recovery after a devastating crash. Then he spotted a poster for the Canadian Death Race. The furthest he had ever competed before was 10 kilometres; he decided to train for ... […]
- Fairfield Family Hosting Fundraiser For Type 1 Diabetes Research on April 17, 2019 at 11:58 am
FAIRFIELD, CT — Fairfield residents Lauren and Steven Field are hosting the third annual "A Night Out for a Cure" fundraising event to benefit Diabetes Research Institute, which is dedicated to ... […]
- Sex, Lies, and the WHO; Diabetes Denial Death; Hidden Prostate Dx Data on April 17, 2019 at 8:32 am
Prosecutors say she hid the girl's type 1 diabetes for 5 years and kept her from being treated, KSDK News reports. Last fall, 14-year-old Emily Hampshire was rushed to a local hospital then ... […]
- An Artificial Pancreas Leader, on Her Life and Career with Type 1 Diabetes on April 17, 2019 at 3:51 am
Jen Block has a reputation for being one of the kindest, most compassionate, and also capable diabetes researchers and clinicians out there. She also lives with type 1 diabetes herself. She's been ... […]
- JDRF research takes aim at Type 1 Diabetes on April 16, 2019 at 11:57 pm
This update will focus on Glucose Control for people with Type One Diabetes (T1D) and the current research on Smart Insulins and the Meds of the Future that will provide greater ability to tightly ... […]
via Bing News